Thenappan Thenappan, M.D.
Thenappan Thenappan (tthenappan@umn.edu) received his medical training from the Tamil Nadu Dr. MGR Medial University, India. He then completed his residency training in Internal Medicine in 2005 at St. Francis Hospital with University of Illinois, Evanston. Following this, he worked as a research fellow in the Center for Pulmonary Hypertension at the University of Chicago. Subsequently, he completed his fellowship training in cardiovascular medicine in 2012 and fellowship training advanced heart failure and transplant cardiology in 2013 at the University of Chicago. Dr. Thenappan is a clinical research scholar interested in translational research in pulmonary vascular disease. During his fellowship training, he worked on redefining the epidemiology of pulmonary arterial hypertension in the current era. His current research focus is on developing novel therapies for right ventricular failure secondary to pulmonary vascular disease. Outside work, he enjoys traveling and spending time with his family. Dr. Thenappan has published on pulmonary vascular diseases\ and right ventricular function in high impact journals including circulation research, Circulation Heart failure, journal of American College of cardiology, journal of American Medical Association, Journal of Heart and Lung Transplantation, American Journal of Residency and Critical care Medicine, European Respiratory Journal, and chest. He is a member of the American Heart Association, American Thoracic society, International Society of Heart and Lung Transplantation, Pulmonary Vascular Research Institute and Pulmonary Hypertension Association.
Recent Publications:
- Thenappan T, Ormiston ML, Ryan JJ, Archer SL. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ. 2018 Mar 14;360:j5492. doi: 10.1136/bmj.j5492. Review. PMID: 29540357
- Prins KW, Rose L, Archer SL, Pritzker M, Weir EK, Kazmirczak F, Misialek JR, Thenappan T. Disproportionate Right Ventricular Dysfunction and Poor Survival in Group 3 Pulmonary Hypertension. Am J Respir Crit Care Med. 2018 Jun 1;197(11):1496-1499. doi: 10.1164/rccm.201712-2405LE. PMID: 29360393
- Thenappan T, Stulak JM, Agarwal R, Maltais S, Shah P, Eckman P, Emani S, Katz JN, Gregoric I, Keebler ME, Uriel N, Adler E, Chuang J, Farrar DJ, Sundareswaran KS, John R. Early intervention for lactate dehydrogenase elevation improves clinical outcomes in patients with the HeartMate II left ventricular assist device: Insights from the PREVENT study. J Heart Lung Transplant. 2018 Jan;37(1):25-32. doi: 10.1016/j.healun.2017.10.017. Epub 2017 Oct 24. PMID: 29153636
- Thenappan T. Pulmonary hypertension in chronic kidney disease: a hemodynamic characterization. Pulm Circ. 2017 Jul-Sep;7(3):567-568. doi: 10.1177/2045893217728462. PMID: 28895505
- Prins KW, Archer SL, Pritzker M, Rose L, Weir EK, Sharma A, Thenappan T. Interleukin-6 is independently associated with right ventricular function in pulmonary arterial hypertension. J Heart Lung Transplant. 2018 Mar;37(3):376-384. PMID: 28893516
- Prins KW, Duval S, Markowitz J, Pritzker M, Thenappan T. Chronic use of PAH-specific therapy in World Health Organization Group III Pulmonary Hypertension: a systematic review and meta-analysis. Pulm Circ. 2017 Mar 24;7(1):145-155. doi: 10.1086/690017. eCollection 2017 Mar. PMID: 28680574
- Prins KW, Tian L, Wu D, Thenappan T, Metzger JM, Archer SL. Colchicine Depolymerizes Microtubules, Increases Junctophilin-2, and Improves Right Ventricular Function in Experimental Pulmonary Arterial Hypertension. J Am Heart Assoc. 2017 May 31;6(6). pii: e006195. doi: 10.1161/JAHA.117.006195. PMID: 28566298
Research projects available:
- Minnesota Pulmonary Hypertension Repository
- Peripheral Blood Proteomic Signature and Right Ventricular Dysfunction in Pulmonary Arterial Hypertension
- Efficacy and Safety of Beta-blockers in PAH